HomeInfrastructurePCMC Medicine Seizure Figures Disputed After FDA Quality Action

PCMC Medicine Seizure Figures Disputed After FDA Quality Action

The Food and Drug Administration (FDA) has seized medicines from the Pimpri Chinchwad Municipal Corporation’s (PCMC) Central Medical Store at Yashwantrao Chavan Memorial Hospital after finding alleged manufacturing-permission and quality violations, but the civic body has disputed the value of the stock and said it had approached the regulator voluntarily.

According to an FDA statement cited in the report, medicines estimated at Rs 1.72 crore were seized from the PCMC store. A further stock valued at Rs 17.58 lakh was seized from the Jejuri MIDC manufacturing facility of Inducare Pharmaceuticals and Research Foundation in Pune district. The combined value was estimated by the FDA at Rs 1.90 crore.

The FDA action was taken under Section 22(1)(c) of the Drugs and Cosmetics Act, 1940. The regulator reportedly identified 10 categories of medicines at the municipal store. Some samples were classified as “Not of Standard Quality” (NSQ), with deficiencies reported in assay, dissolution, description, uniformity of weight and labelling. The FDA also said the manufacturer lacked valid permissions to produce certain medicines supplied to the civic body.

A show-cause notice was issued to the company on October 29, 2026, over the alleged manufacture and supply of medicines without the required permissions. The FDA inspected the company’s Jejuri facility on October 30 and seized additional stock. It said prosecution proceedings against the manufacturer would be initiated.

PCMC, however, said the FDA had not conducted a raid at YCM Hospital. The civic administration said it had sought quality testing after receiving a complaint from its Thergaon hospital on February 14, 2026, regarding B-Complex with Zinc capsules sold under the name CareZinc. PCMC wrote to the FDA on February 23 requesting sample collection and testing, and said the stock had already been withdrawn from use and kept aside.

The civic body said the FDA’s report, received on July 16, declared the medicine NSQ. PCMC subsequently blacklisted Inducare Pharmaceuticals and Research Foundation for three years from September 8 and barred its supplier, Shree Vinayak Pharma, Pune, from supplying medicines to the corporation for the same period.

PCMC further said the FDA tested 12 types of medicines supplied by Shree Vinayak Pharma on July 27. According to the civic administration, 11 were declared NSQ and two were reported to meet prescribed quality standards. The figures in this account overlap, and the report does not explain how 11 medicines could be classified NSQ while two of 12 were found compliant.

The civic body said the FDA took possession of the stock of 11 medicines on November 4 for further testing and action. It valued that stock at Rs 11.95 lakh and disputed reports that medicines worth Rs 1.72 crore had been seized from its store. PCMC also said no payment had been made to the supplier for the disputed stock.

Health medical officer Dr Laxman Gophane said the corporation had approached the FDA to protect medicine quality and patient safety. Additional municipal commissioner Kuldeep Jangam said action had been taken against the manufacturer and supplier based on the findings.

The available accounts therefore establish regulatory action and municipal restrictions on the supplier, but the value and precise scope of the stock seized from the PCMC facility remain unresolved. The FDA seizure records, laboratory reports and PCMC procurement documents would be needed to reconcile the competing figures and confirm the final status of the medicines.



RELATED ARTICLES

Most Popular

Latest News